Bristol Myers Squibb Competitors and Similar CompaniesClear all

Daiichi Sankyo's competitors and similar companies include Regeneron Pharmaceuticals, Gilead Sciences, Edwards Lifesciences, Lonza, Catalent, Pfizer, Johnson & Johnson, AbbVie, Merck Group, AstraZeneca and Eli Lilly.
Daiichi Sankyo
Daiichi Sankyo
Daiichi Sankyo (第一三共株式会社) is a developer of pharmaceutical products.
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals is a biopharmaceutical company that develops, manufactures, and markets medicines.
Gilead Sciences
Gilead Sciences
Gilead Sciences is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of medicines.
Edwards Lifesciences
Edwards Lifesciences
Edwards Lifesciences is a provider of patient-focused medical solutions for structural heart disease and critical care monitoring.
Lonza
Lonza
Lonza Group is a company that supplies active ingredients, chemical intermediates, and biotechnology solutions to the pharmaceutical and agrochemical industries.
Catalent
Catalent
Catalent is a company that develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, vaccines, and consumer health products.
Pfizer
Pfizer
Pfizer is a research-based biopharmaceutical company engaged in the discovery, development, manufacture, and distribution of healthcare products.
Johnson & Johnson
Johnson & Johnson
Johnson & Johnson (J&J) is a company that engages in the research and development, manufacture, and sale of a range of products in the healthcare field.
AbbVie
AbbVie
AbbVie is a pharmaceutical company engaged in the research and development, manufacturing, commercialization, and sale medicines and therapies.
Merck Group
Merck Group
Merck Group is a science and technology company.
AstraZeneca
AstraZeneca
AstraZeneca is a biopharmaceutical company specializing in the discovery, development, manufacturing, and marketing of prescription medicines.
Eli Lilly
Eli Lilly
Eli Lilly is a company that discovers, develops, manufactures, and markets pharmaceutical products.
Founding Date
Founding Date
2005
Founding Date
1988
Founding Date
1987
Founding Date
1958
Founding Date
1897
Founding Date
2007
Founding Date
1849
Founding Date
1886
Founding Date
2013
Founding Date
1668
Founding Date
1999
Founding Date
1876
Type
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Tokyo, JP HQ
Wien, AT
Braine L'alleud, BE
Sao Paulo, BR
São Paulo, BR
Beijing, CN
Shanghai, CN
see more
Locations
Tarrytown, US HQ
Mississauga, CA
München, DE
Bengaluru, IN
Dublin, IE
Limerick, IE
Tokyo, JP
see more
Locations
Foster City, US HQ
Buenos Aires, AR
Melbourne, AU
Wien, AT
Machelen, BE
São Paulo, BR
Edmonton, CA
see more
Locations
Irvine, US HQ
Macquarie Park, AU
Wien, AT
Dilbeek, BE
São Paulo, BR
Mississauga, CA
Shanghai, CN
see more
Locations
Basel, CH HQ
Baulkham Hills, AU
Antwerpen, BE
Bornem, BE
Verviers, BE
Rio De Janeiro, BR
Dorval, CA
see more
Locations
Somerset, US HQ
Buenos Aires, AR
Bruxelles, BE
Charleroi, BE
Charleroi, BE
Charleroi, BE
Indaiatuba, BR
see more
Locations
New York, US HQ
Buenos Aires, AR
Villa Adelina, AR
Bentley, AU
Footscray, AU
Mulgrave, AU
Sydney, AU
see more
Locations
New Brunswick, US HQ
Buenos Aires, AR
Sydney, AU
Ultimo, AU
Wien, AT
Minsk, BY
Beerse, BE
see more
Locations
Lake Bluff, US HQ
Alger, DZ
Buenos Aires, AR
Mascot, AU
Wien, AT
Wavre, BE
Sarajevo, BA
see more
Locations
Darmstadt, DE HQ
Buenos Aires, AR
Bayswater, AU
Macquarie Park, AU
Wien, AT
Hoeilaart, BE
Rio De Janeiro, BR
see more
Locations
Cambridge, GB HQ
Alger, DZ
Buenos Aires, AR
Haedo, AR
Macquarie Park, AU
Macquarie Park, AU
North Ryde, AU
see more
Locations
Indianapolis, US HQ
Buenos Aires, AR
Sydney, AU
Wien, AT
Brussel, BE
São Paulo, BR
Toronto, CA
see more
Employees
Employees
17,435
Employees
12,2563% increase
Employees
18,0006% increase
Employees
17,30010% increase
Employees
18,000
Employees
17,8006% decrease
Employees
83,0005% increase
Employees
152,7008% increase
Employees
50,000
Employees
62,3451% decrease
Employees
89,900
Employees
39,00011% increase
Valuation ($)
Valuation ($)
72.5 b
Valuation ($)
119.6 b
Valuation ($)
90.4 b
Valuation ($)
53.9 b
Valuation ($)
N/A
Valuation ($)
10.5 b
Valuation ($)
157 b
Valuation ($)
359.6 b
Valuation ($)
296.7 b
Valuation ($)
73.1 b
Valuation ($)
241.9 b
Valuation ($)
903.3 b
Twitter followers
Twitter followers
683
Twitter followers
32.5 k
Twitter followers
73.8 k
Twitter followers
10.6 k
Twitter followers
8.1 k
Twitter followers
19 k
Twitter followers
491.8 k
Twitter followers
250 k
Twitter followers
78.9 k
Twitter followers
24.9 k
Twitter followers
303.8 k
Twitter followers
N/A
Number of tweets (last 30 days)
Number of tweets (last 30 days)
N/A
Number of tweets (last 30 days)
4
Number of tweets (last 30 days)
22
Number of tweets (last 30 days)
8
Number of tweets (last 30 days)
1
Number of tweets (last 30 days)
116
Number of tweets (last 30 days)
16
Number of tweets (last 30 days)
8
Number of tweets (last 30 days)
52
Number of tweets (last 30 days)
51
Number of tweets (last 30 days)
22
Number of tweets (last 30 days)
N/A
Average likes per tweet (last 30 days)
Average likes per tweet (last 30 days)
N/A
Average likes per tweet (last 30 days)
4.8
Average likes per tweet (last 30 days)
48.1
Average likes per tweet (last 30 days)
5.4
Average likes per tweet (last 30 days)
15
Average likes per tweet (last 30 days)
0.4
Average likes per tweet (last 30 days)
63.4
Average likes per tweet (last 30 days)
13.9
Average likes per tweet (last 30 days)
5.2
Average likes per tweet (last 30 days)
5.9
Average likes per tweet (last 30 days)
14.1
Average likes per tweet (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
Percentage of tweets with engagement (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
33.62%
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
75%
Percentage of tweets with engagement (last 30 days)
88.46%
Percentage of tweets with engagement (last 30 days)
96.08%
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
N/A

Financial

Revenue (est.)
Revenue (est.)
¥1t (FY, 2021)
Revenue (est.)
$13.1b (FY, 2023)
Revenue (est.)
$27.1b (FY, 2023)
Revenue (est.)
$6b (FY, 2023)
Revenue (est.)
CHF6.7b (FY, 2023)
Revenue (est.)
$4.3b (FY, 2023)
Revenue (est.)
$58.5b (FY, 2023)
Revenue (est.)
$85.2b (FY, 2023)
Revenue (est.)
$54.3b (FY, 2023)
Revenue (est.)
€21b (FY, 2023)
Revenue (est.)
$45.8b (FY, 2023)
Revenue (est.)
$34.1b (FY, 2023)
Cost of goods
Cost of goods
¥353.3b (FY, 2021)
Cost of goods
N/A
Cost of goods
$6.5b (FY, 2023)
Cost of goods
$1.4b (FY, 2023)
Cost of goods
CHF4.1b (FY, 2023)
Cost of goods
$3.2b (FY, 2023)
Cost of goods
$25b (FY, 2023)
Cost of goods
$26.6b (FY, 2023)
Cost of goods
$20.4b (FY, 2023)
Cost of goods
€7.3b (FY, 2023)
Cost of goods
$7.2b (FY, 2023)
Cost of goods
$7.1b (FY, 2023)
Gross profit
Gross profit
¥691.6b (FY, 2021)
Gross profit
N/A
Gross profit
$20.6b (FY, 2023)
Gross profit
$4.6b (FY, 2023)
Gross profit
CHF2.6b (FY, 2023)
Gross profit
$1b (FY, 2023)
Gross profit
$33.5b (FY, 2023)
Gross profit
$58.6b (FY, 2023)
Gross profit
$33.9b (FY, 2023)
Gross profit
€13.9b (FY, 2023)
Gross profit
$39.8b (FY, 2023)
Gross profit
$27b (FY, 2023)
Net income
Net income
¥67b (FY, 2021)
Net income
$4b (FY, 2023)
Net income
$5.6b (FY, 2023)
Net income
$1.4b (FY, 2023)
Net income
CHF655m (FY, 2023)
Net income
($256m) (FY, 2023)
Net income
$2.2b (FY, 2023)
Net income
$35.2b (FY, 2023)
Net income
$4.9b (FY, 2023)
Net income
€2.8b (FY, 2023)
Net income
$6b (FY, 2023)
Net income
$5.2b (FY, 2023)

Operating

Countries
Countries
N/A
Countries
N/A
Countries
35 (FY, 2021)
Countries
100 (FY, 2022)
Countries
28 (FY, 2022)
Countries
80 (FY, 2023)
Countries
125 (FY, 2021)
Countries
N/A
Countries
70 (FY, 2022)
Countries
66 (FY, 2021)
Countries
130 (FY, 2021)
Countries
120 (FY, 2021)
Manufacturing Facilities
Manufacturing Facilities
13 (Jun, 2022)
Manufacturing Facilities
N/A
Manufacturing Facilities
N/A
Manufacturing Facilities
7 (FY, 2022)
Manufacturing Facilities
N/A
Manufacturing Facilities
N/A
Manufacturing Facilities
N/A
Manufacturing Facilities
N/A
Manufacturing Facilities
19 (FY, 2022)
Manufacturing Facilities
N/A
Manufacturing Facilities
N/A
Manufacturing Facilities
N/A
Manufacturing Facilities (United States)
Manufacturing Facilities (United States)
N/A
Manufacturing Facilities (United States)
N/A
Manufacturing Facilities (United States)
N/A
Manufacturing Facilities (United States)
N/A
Manufacturing Facilities (United States)
N/A
Manufacturing Facilities (United States)
N/A
Manufacturing Facilities (United States)
N/A
Manufacturing Facilities (United States)
28 (FY, 2022)
Manufacturing Facilities (United States)
11 (FY, 2022)
Manufacturing Facilities (United States)
N/A
Manufacturing Facilities (United States)
N/A
Manufacturing Facilities (United States)
N/A
Phase I Trials Products
Phase I Trials Products
16 (FY, 2018)
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
27 (FY, 2021)
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
27 (FY, 2019)
Phase II Trials Products
Phase II Trials Products
7 (FY, 2018)
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
25 (FY, 2021)
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
8 (FY, 2021)
Phase III Trials Products
Phase III Trials Products
7 (FY, 2018)
Phase III Trials Products
N/A
Phase III Trials Products
9 (FY, 2021)
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
27 (FY, 2021)
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
10 (FY, 2021)
Products
Products
N/A
Products
11 (FY, 2022)
Products
21 (FY, 2021)
Products
N/A
Products
N/A
Products
8 k (FY, 2023)
Products
N/A
Products
N/A
Products
N/A
Products
300 k (FY, 2021)
Products
N/A
Products
N/A
Trademarks
Trademarks
112 (Jun, 2022)
Trademarks
20 (FY, 2022)
Trademarks
N/A
Trademarks
N/A
Trademarks
N/A
Trademarks
N/A
Trademarks
N/A
Trademarks
N/A
Trademarks
N/A
Trademarks
N/A
Trademarks
N/A
Trademarks
N/A

Funding

Total funding raised
Total funding raised
N/A
Total funding raised
$ 53.9m
Total funding raised
N/A
Total funding raised
$ 307.2m
Total funding raised
N/A
Total funding raised
$ 650m
Total funding raised
N/A
Total funding raised
N/A
Total funding raised
N/A
Total funding raised
$ 121m
Total funding raised
$ 1b
Total funding raised
N/A
For sources of this data, please see the company profile

View Company Profiles

Regeneron Pharmaceuticals
HQ
Tarrytown, US
Employees
12,256↑ 3% increase

Regeneron Pharmaceuticals is a biopharmaceutical company that develops, manufactures, and markets medicines.

View company
Gilead Sciences
HQ
Foster City, US
Employees
18,000↑ 6% increase

Gilead Sciences is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of medicines.

View company
Edwards Lifesciences
HQ
Irvine, US
Employees
17,300↑ 10% increase

Edwards Lifesciences is a provider of patient-focused medical solutions for structural heart disease and critical care monitoring.

View company
Lonza
HQ
Basel, CH
Employees
18,000

Lonza Group is a company that supplies active ingredients, chemical intermediates, and biotechnology solutions to the pharmaceutical and agrochemical industries.

View company